Pharvaris Stock Earnings Estimates Reduced by HC Wainwright

Key Points

• HC Wainwright cut Pharvaris’ FY2029 EPS estimate to $2.88 from $3.09, while maintaining a “Buy” rating and projecting FY2030 EPS of $6.62.
• Analyst sentiment remains broadly positive, with 13 Buy ratings, one Hold, and one Sell; the stock has an average “Moderate Buy” rating and a consensus price target of $58.60.
• Pharvaris shares opened at $31.12, below their 50-day moving average of $34.93, while insiders sold roughly 513,000 shares worth $18.6 million over the past three months.

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Investment analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for shares of Pharvaris in a report released on Tuesday, October 6th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $2.88 for the year, down from their previous estimate of $3.09. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Pharvaris' FY2030 earnings at $6.62 EPS.

A number of other research firms have also recently weighed in on PHVS. HSBC upgraded shares of Pharvaris to an "overweight" rating in a research report on Thursday, August 13th. Wedbush boosted their target price on shares of Pharvaris from $42.00 to $50.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 9th. UBS Group set a $60.00 price target on shares of Pharvaris in a research report on Tuesday. Leerink Partners raised their price target on shares of Pharvaris from $50.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, September 9th. Finally, Rosenblatt Securities set a $60.00 price objective on Pharvaris in a report on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Pharvaris presently has an average rating of "Moderate Buy" and an average price target of $58.60.

Pharvaris Price Performance

Shares of NASDAQ:PHVS opened at $31.12 on Wednesday. The business's 50 day moving average price is $34.93 and its 200-day moving average price is $32.26. Pharvaris has a 1 year low of $20.65 and a 1 year high of $43.25. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -10.20 and a beta of -2.46.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06).

Institutional Trading of Pharvaris

Several hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP acquired a new position in Pharvaris in the second quarter valued at approximately $41,000. CoreCap Advisors LLC acquired a new stake in Pharvaris during the second quarter worth $93,000. Public Employees Retirement System of Ohio acquired a new stake in Pharvaris during the second quarter worth $196,000. Algert Global LLC purchased a new stake in Pharvaris in the second quarter valued at $238,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Pharvaris in the second quarter valued at $273,000.

Insider Activity at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 30,000 shares of the company's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $38.30, for a total value of $1,149,000.00. Following the completion of the sale, the insider directly owned 56,450 shares in the company, valued at $2,162,035. This represents a 34.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elisabeth Bjork sold 52,500 shares of the firm's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $37.89, for a total value of $1,989,225.00. Following the completion of the sale, the director directly owned 15,167 shares of the company's stock, valued at $574,677.63. This trade represents a 77.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 513,102 shares of company stock valued at $18,643,666 in the last three months.

Pharvaris Company Profile

Pharvaris N.V. NASDAQ: PHVS is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company's lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.